Mitoquinone mesylate

Mitoquinone mesylate (MitoQ) is a modified form of CoQ10 (ubiquinone) conjugated to a triphenylphosphonium cation, allowing it to accumulate in mitochondria at concentrations 100-1000x higher than standard CoQ10. Marketed as a mitochondria-targeted antioxidant for aging and cellular health. NO GRADED OUTCOMES - research is limited but growing. Some human studies show vascular and metabolic benefits. More targeted than regular CoQ10 for mitochondrial oxidative stress. Premium priced patented compound. Promising concept but evidence for most marketed claims is still developing.

Quick Answer

What it is

Key findings

Grade C: Oxidative Stress
Grade C: Vascular Function
Grade C: Aerobic Exercise Performance

Safety

An exploratory open-label non-randomized pilot trial (Chen et al., 2024) in 80 individuals with high-risk SARS-CoV-2 exposure found 30% infection rate with MitoQ (20 mg/day for 14 days) vs.

ℹ️ Quick Facts: Mitoquinone mesylate

Quick Facts: Mitoquinone mesylate

Best Evidence:Grade C
Conditions Studied:4
Research Outcomes:6
Key Effect:Aerobic Exercise Performance

Outcomes by grade:

4 conditions · 6 outcomes

Detailed Outcomes

Oxidative Stress

Multiple small RCTs demonstrate MitoQ reduces oxidative stress biomarkers. Rossman et al. (2018) found lower plasma oxidized LDL in 20 older adults. Broome et al. (2021) reported reduced F2-isoprostanes post-exercise in 19 cyclists. Moradbaki et al. (2025) showed improved GPx, CAT, SOD, and reduced MDA in 42 septic shock patients. Effects consistent across populations.

81 participants

moderate↓Improves

Vascular Function

Two small RCTs found MitoQ (20 mg/day for 4-6 weeks) improved brachial artery flow-mediated dilation. Rossman et al. (2018) reported a 42% improvement in FMD in 20 healthy older adults, while Kirkman et al. (2023) showed significant FMD improvement in 18 patients with chronic kidney disease. Rossman also found reduced aortic stiffness in participants with elevated baseline levels.

38 participants

moderate↑Improves

Aerobic Exercise Performance

Two small RCTs in middle-aged men found MitoQ (20 mg/day) improved exercise performance. Broome et al. (2021) reported a 1.3% improvement in 8 km cycling time trial completion with 4.4% higher average power in 19 trained cyclists. Broome et al. (2022) found greater training-induced peak power improvements in 23 untrained men, though VO2peak gains were comparable to placebo.

42 participants

small↑Improves

Parkinson's Disease Progression

The largest MitoQ trial to date, a 12-month multicenter RCT (Snow et al., 2010) in 128 newly diagnosed Parkinson's disease patients, found NO difference between MitoQ and placebo on any measure of disease progression (UPDRS). This well-powered negative result suggests MitoQ does not slow PD progression.

128 participants

small↓Improves

Liver Enzymes (ALT/AST)

A Phase II RCT (Gane et al., 2010) in 30 patients with chronic hepatitis C found that MitoQ (40 or 80 mg/day for 28 days) significantly reduced serum ALT and AST levels, suggesting decreased hepatic necroinflammation. However, MitoQ did not affect HCV viral load. Single study requiring replication.

30 participants

moderate↓Improves

SARS-CoV-2 Infection Risk

An exploratory open-label non-randomized pilot trial (Chen et al., 2024) in 80 individuals with high-risk SARS-CoV-2 exposure found 30% infection rate with MitoQ (20 mg/day for 14 days) vs. 75% in matched controls. Supported by preclinical data (Petcherski et al., 2022, preprint) showing nanomolar antiviral potency in cell and mouse models. Non-randomized design limits conclusions.

80 participants

moderate↓Improves

Evidence by Condition

Best grade per condition (each condition may have multiple outcomes)

CAerobic Exercise Performance

1 outcome · 2 studies

↑Aerobic Exercise PerformanceImproves

CAntioxidant Status

1 outcome · 3 studies

↓Oxidative StressImproves

CCardiovascular Health

1 outcome · 2 studies

↑Vascular FunctionImproves

DAcute Respiratory Infection (ARI)

1 outcome · 2 studies

↓SARS-CoV-2 Infection RiskImproves

Research Citations (11)

A pilot double-blind, placebo-controlled, randomized clinical trial of MitoQ in the treatment of septic shock

Naunyn-Schmiedeberg's Archives of Pharmacology (2025)

PMID: 40820063

Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls

EBioMedicine (2024)

PMID: 38471990

Oral subchronic toxicity study and genetic toxicity evaluation of mitoquinone mesylate

Journal of Applied Toxicology (2024)

PMID: 38860421

Effects of a mitochondrial-targeted ubiquinol on vascular function and exercise capacity in chronic kidney disease: a randomized controlled pilot study

American Journal of Physiology - Renal Physiology (2023)

PMID: 37560769

MitoQ supplementation augments acute exercise-induced increases in muscle PGC1alpha mRNA and improves training-induced increases in peak power independent of mitochondrial content and function in untrained middle-aged men

Redox Biology (2022)

PMID: 35623315

Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models

bioRxiv (2022)

PMID: 35233569

Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists

Journal of the International Society of Sports Nutrition (2021)

PMID: 34419082

Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults

Hypertension (2018)

PMID: 29661838

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients

Liver International (2010)

PMID: 20492507

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Movement Disorders (2010)

PMID: 20568096

Related Supplements

Haskap Berry

3 shared conditions · 8 outcomes

Haskap berries (blue honeysuckle) are antioxidant-rich berries native to northern regions, called 'fruit of longevity' in Japan. Rich in anthocyanins (particularly cyanidin-3-glucoside), vitamin C, and polyphenols. NO GRADED OUTCOMES - limited human research. Anthocyanin content exceeds blueberries. May have cardiovascular, anti-inflammatory, and cognitive benefits based on similar berry research, but haskap-specific studies are lacking. Safe as a food. Available fresh, frozen, or as supplements. Emerging berry gaining research interest due to high polyphenol content.

Vitamin C

2 shared conditions · 262 outcomes

Vitamin C, or ascorbic acid, is an essential vitamin and a very popular supplement due to its antioxidant properties, safety profile, and low price. Many people supplement with vitamin C because it is believed to reduce symptoms of the common cold.

Umckaloabo

2 shared conditions · 42 outcomes

Umckaloabo is a common name for the root extract of Pelargonium sidoides, a member of the geranium family. The most frequently studied use for umckaloabo is in the treatment of respiratory infection symptoms.

Tetraselmis Chuii

2 shared conditions · 7 outcomes

Tetraselmis chuii is a marine microalgae approved as a Novel Food in the EU. Rich in protein, omega-3 fatty acids, and antioxidants. Marketed as a sustainable superfood. NO GRADED OUTCOMES - human research is very limited. Primarily used in aquaculture as fish feed. Potential as a sustainable nutrient source but lacks clinical evidence for specific health claims. Generally safe as food.

Terminalia Chebula

2 shared conditions · 12 outcomes

Terminalia chebula (Haritaki) is one of the three fruits in Triphala, an important Ayurvedic formula. Considered 'king of medicines' in Tibet. Contains tannins and antioxidants. Traditional uses include digestive issues, oral health, and as a general 'rejuvenative.' NO GRADED OUTCOMES - human research is very limited. Preclinical research shows antimicrobial, antioxidant, and anti-diabetic potential. Primarily available as part of Triphala rather than alone.

Squalene

2 shared conditions · 4 outcomes

Squalene is a triterpene found in olive oil, shark liver oil, and produced endogenously in humans as a cholesterol precursor. Some research suggests benefits for cholesterol and immune function. NO GRADED OUTCOMES. The 'sharks don't get cancer' myth was debunked (sharks do get cancer), but squalene may have modest health benefits. Available from plant sources (olive, amaranth) for those avoiding shark products. Used as vaccine adjuvant (MF59). Generally safe.

Society garlic

2 shared conditions · 6 outcomes

Society garlic is a South African plant (not true garlic) traditionally used for infections and as food flavoring. Contains sulfur compounds similar to garlic. Limited research suggests possible cardiovascular and antimicrobial effects. Some animal studies show testosterone effects, but evidence is preliminary. NO GRADED OUTCOMES. Not widely available as a supplement. Safer than true garlic with milder taste (hence 'society' - can be eaten before social events).

Slippery Elm

2 shared conditions · 4 outcomes

Slippery elm is a North American tree whose inner bark contains mucilage with soothing/coating properties. Traditionally used for sore throat, coughs, GI complaints, and skin irritation. NO GRADED OUTCOMES - clinical research is limited. The mucilage provides mechanical soothing, similar to other demulcent herbs. Generally safe. Often used in throat lozenges and teas. May interfere with medication absorption.